FGFR2 and cholangiocarcinoma: Approved by FDA for previouslytreated, unresectable, advanced/metastatic CCA with FGFR2 alterations. Phase III trial (FIGHT-302) versus chemotherapy as first-line treatment in CCA is ongoing.